Revealed: Keith Kohl’s AI Drug Development Stock (Algo Meds)

Another day, another stock picker recommended an AI stock.

Today we're going to look at Keith Kohl and his new stock teaser, which claims to give you access to the best AI drug development stock.

It's all in a report called AlgoMeds.

However, Keith wants thousands of dollars to give away the stock, but I have good news!

He left enough clues in the presentation to figure out the stock, and I reveal them below.

Additionally, I'll break down the stock so you can determine if it's worth investing in.

Let's get started now!

Breaking Down The Teaser

2023 is going down as the year of AI.

It's the newest technology everyone is going bonkers over, and AI is pretty much driving all the gains on the market this year.

Stock pickers are all recommending their favorite AI stocks as well, and that's what Keith Kohl is doing here.

There are a million different ways to play AI, ranging from AI chips to AI companies, and Keith is recommending an AI company that focuses on AI drug discovery.

AI drug discovery is the use of artificial intelligence (AI) to accelerate the discovery and development of new drugs. AI can be used to automate tasks, analyze large datasets, and make predictions that would be difficult or impossible for humans to do on their own.

There are many different ways that AI is being used in drug discovery. For example, AI can be used to:

• Identify new drug targets: AI can be used to analyze large datasets of genomic data and other biological information to identify new proteins and other molecules that could be targeted by drugs.
• Design new drug molecules: AI can be used to generate new drug molecules that are likely to bind to specific drug targets and have the desired therapeutic effects.
• Predict the properties of drug molecules: AI can be used to predict the toxicity, efficacy, and other properties of drug molecules without having to test them in the lab.
• Identify drug combinations: AI can be used to identify combinations of drugs that are more effective than either drug alone.

AI drug discovery is still in its early stages of development, but it has the potential to revolutionize the way that new drugs are discovered and developed. AI could help to reduce the time and cost of drug discovery, and it could lead to the development of new and more effective drugs for a wide range of diseases.

The company that Keith is recommending is Exscientia.

What Is Exscientia?

Exscientia is an AI-driven pharmatech company that uses artificial intelligence (AI) and machine learning (ML) to discover and design novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe and efficacious compounds for clinical testing in humans. Exscientia is focused on the discovery and development of small-molecule drug candidates.

Exscientia's AI platform is trained on a massive dataset of chemical and biological information, including the structures of known drugs and proteins, as well as the results of preclinical and clinical trials. This allows the platform to generate and evaluate millions of potential drug candidates in a fraction of the time it would take using traditional methods.

Exscientia's drug discovery process begins with the identification of a target protein or pathway that is involved in the disease of interest. The company's AI platform then generates a large number of potential drug candidates that are predicted to interact with the target protein in a way that will have a therapeutic effect.

These drug candidates are then screened using a variety of computational and experimental methods to identify those that are most likely to be safe and effective in humans. The most promising candidates are then advanced into preclinical and clinical development.

Exscientia has a number of drug candidates in development for a variety of diseases, including cancer, infectious diseases, and neurodegenerative disorders. The company's first drug candidate, an oral treatment for Alzheimer's disease, is currently in Phase 2 clinical trials.

Exscientia is a pioneer in the use of AI for drug discovery. The company's technology platform has the potential to revolutionize the way that new drugs are developed. By accelerating the drug discovery process, Exscientia can help to bring new treatments to patients more quickly and efficiently.

Here are some of the key features of Exscientia's AI platform:

• It is trained on a massive dataset of chemical and biological information.
• It can generate and evaluate millions of potential drug candidates in a fraction of the time it would take using traditional methods.
• It can predict the safety and efficacy of drug candidates before they are tested in animals or humans.
• It can be used to identify new drug targets and to develop personalized treatments for patients.

Exscientia has partnered with a number of leading pharmaceutical companies, including Bristol Myers Squibb, Evotec, and Sanofi. These partnerships allow Exscientia to access the resources and expertise of these companies to develop and commercialize its drug candidates.

Exscientia is a well-funded company with a strong track record of innovation. The company has raised over $800 million in funding from investors such as the Bill & Melinda Gates Foundation and SoftBank Vision Fund.

Is Exscientia Worth Investing In?

Exscientia is a relatively new company, and it is still in the early stages of developing its pipeline of drugs. This means that there is a lot of risk associated with investing in the company's stock. However, Exscientia has a strong team and a promising technology platform. If the company is able to successfully develop and commercialize its drugs, its stock price could rise significantly.

Here's a look at everything to know about this stock:

Financial Health

Exscientia is a clinical-stage AI-driven pharmatech company that is still in the process of developing its pipeline and platform. As such, it is not yet profitable and generates most of its revenue from collaboration agreements with other pharmaceutical companies.

For the full year 2022, Exscientia reported revenue of $117.8 million, up from $85.3 million in 2021. However, the company also incurred a net loss of $73.1 million in 2022, compared to a net income of $8.1 million in 2021.

Exscientia's financial health is strong, with a cash balance of $610.9 million as of December 31, 2022. This gives the company a runway of several years to continue investing in its pipeline and platform.

However, it is important to note that Exscientia is still a relatively new company and has not yet generated any revenue from its own drug sales. As such, it is important to monitor the company's financial performance closely in the coming years to see if it can successfully transition from a research and development company to a commercial drug developer.

Overall, Exscientia's financial health is strong, but it is still too early to say definitively whether the company will be successful in the long term.

Industry And Market Trends

Exscientia is a clinical-stage AI-driven pharmatech company that is using artificial intelligence (AI) to revolutionize the discovery, design, and development of new drug candidates. The company's AI platform can generate novel drug candidates in a fraction of the time and cost of traditional drug discovery methods.

The global pharmaceutical market is expected to reach $1.5 trillion by 2023, and the AI drug discovery market is expected to grow at a compound annual growth rate (CAGR) of 40% over the next five years. This growth is being driven by a number of factors, including the rising prevalence of chronic diseases, the increasing demand for personalized medicine, and the growing adoption of AI in healthcare.

Exscientia is well-positioned to capitalize on these trends. The company has a strong pipeline of drug candidates in development, and it has partnerships with some of the world's leading pharmaceutical companies. In addition, Exscientia is constantly innovating and improving its AI platform.

Here are some of the key industry and market trends that are relevant to Exscientia:

• The rising prevalence of chronic diseases: Chronic diseases, such as cancer, heart disease, and diabetes, are a major global health problem. The prevalence of these diseases is expected to continue to rise in the coming years, due to factors such as population aging and unhealthy lifestyles. This is creating a growing demand for new and innovative drugs to treat these diseases.
• The increasing demand for personalized medicine: Personalized medicine is an approach to healthcare that takes into account the individual characteristics of each patient, such as their genetics and lifestyle. This allows for more targeted and effective treatment. AI is playing an increasingly important role in personalized medicine, as it can be used to identify new drug targets and to develop personalized treatment plans.
• The growing adoption of AI in healthcare: AI is being adopted at a rapid pace across the healthcare sector, from drug discovery to diagnostics to patient care. AI is being used to improve the efficiency and effectiveness of healthcare delivery, and to develop new and innovative products and services.

Exscientia is at the forefront of the AI drug discovery revolution. The company's AI platform has the potential to significantly accelerate the drug discovery process and to bring new drugs to market faster. This is a major opportunity for the company, as the global pharmaceutical market is growing rapidly and there is a high demand for new and innovative drugs.

Competitive Position 

Exscientia's competitive position is strong, but it is still a relatively new company and faces a number of challenges.

On the plus side, Exscientia has a number of key advantages over its competitors:

• A strong pipeline of drug candidates in development: Exscientia has a pipeline of over 20 drug candidates in development, targeting a wide range of therapeutic areas, including cancer, immunology, and infectious diseases.
• Partnerships with leading pharmaceutical companies: Exscientia has partnerships with a number of leading pharmaceutical companies, such as Bristol Myers Squibb, Sanofi, and GSK. These partnerships provide Exscientia with access to funding, expertise, and resources to help develop and commercialize its drug candidates.
• A leading AI platform for drug discovery: Exscientia's AI platform is one of the most advanced in the world. The company has invested heavily in its AI platform and has a team of world-class scientists and engineers.

However, Exscientia also faces a number of challenges:

• Competition from other AI drug discovery companies: There are a number of other companies developing AI-powered drug discovery platforms. This competition could make it difficult for Exscientia to maintain its competitive advantage.
• Regulatory hurdles: The regulatory hurdles for new drug approvals are high and expensive. Exscientia will need to successfully navigate these hurdles in order to bring its drug candidates to market.
• Lack of profitability: Exscientia is not yet profitable and generates most of its revenue from collaboration agreements with other pharmaceutical companies. The company will need to start generating revenue from its own drug sales in order to become sustainable.

Overall, Exscientia is a well-positioned company with a strong pipeline of drug candidates and a leading AI platform. However, the company still faces a number of challenges, such as competition from other AI drug discovery companies, regulatory hurdles, and the lack of profitability.

Earnings

Exscientia is not yet profitable, so its earnings are negative. The company's earnings per share (EPS) for the first half of 2023 were -$0.19. This is in line with analyst expectations.

Exscientia is expected to remain unprofitable in the near future, as it invests heavily in its pipeline and platform. However, the company is expected to become profitable in the medium to long term, as it starts generating revenue from its own drug sales.

Analysts are forecasting that Exscientia will report an EPS of -$0.39 for the full year 2023. However, it is important to note that these are just estimates and the company's actual earnings could be different.

Investors who are considering investing in Exscientia should not focus on the company's earnings in the near term. Instead, they should focus on the company's long-term potential and its ability to successfully develop and commercialize its drug candidates.

Valuation

Exscientia is currently valued at around $2.9 billion. This valuation is based on a number of factors, including the company's pipeline of drug candidates, its AI platform, and its partnerships with leading pharmaceutical companies.

However, it is important to note that Exscientia is still a relatively new company and has not yet generated any revenue from its own drug sales. As such, its valuation is based on its future potential rather than its current performance.

Some analysts believe that Exscientia is overvalued, given its lack of profitability and the high level of risk associated with investing in a new biotechnology company. Others believe that Exscientia is undervalued, given its strong pipeline of drug candidates and its leading AI platform.

Ultimately, it is up to each individual investor to decide whether they believe that Exscientia is overvalued or undervalued. Investors should carefully consider the company's competitive position, its pipeline of drug candidates, and its financial performance before making an investment decision.

Here are some of the key factors that investors should consider when evaluating Exscientia's valuation:

• Pipeline of drug candidates: Exscientia has a pipeline of over 20 drug candidates in development, targeting a wide range of therapeutic areas. The company's pipeline includes both early-stage and late-stage drug candidates.
• AI platform: Exscientia's AI platform is one of the most advanced in the world. The company has invested heavily in its AI platform and has a team of world-class scientists and engineers.
• Partnerships: Exscientia has partnerships with a number of leading pharmaceutical companies. These partnerships provide Exscientia with access to funding, expertise, and resources to help develop and commercialize its drug candidates.
• Financial performance: Exscientia is not yet profitable and generates most of its revenue from collaboration agreements with other pharmaceutical companies. The company will need to start generating revenue from its own drug sales in order to become sustainable.

Investors should also consider the valuation of Exscientia's peers when evaluating its valuation. Exscientia's peers are other biotechnology companies that are developing AI-powered drug discovery platforms.

Overall, Exscientia is a company with a lot of potential. However, it is also a company with a lot of risk. Investors who are considering investing in Exscientia should carefully consider the company's valuation and the risks involved.

Long Term Growth Potential:

Exscientia has the potential to be a major player in the pharmaceutical industry in the long term. The company's AI platform has the potential to revolutionize the drug discovery process and to bring new drugs to market faster.

Exscientia is also well-positioned to capitalize on the growing demand for personalized medicine. The company's AI platform can be used to identify new drug targets and to develop personalized treatment plans.

In addition, Exscientia's partnerships with leading pharmaceutical companies give it access to the funding, expertise, and resources it needs to develop and commercialize its drug candidates.

Here are some of the key factors that support Exscientia's long-term growth potential:

• Growing demand for new drugs: The global pharmaceutical market is expected to grow rapidly in the coming years, due to factors such as the rising prevalence of chronic diseases and the increasing demand for personalized medicine.
• Advantages of AI drug discovery: AI drug discovery has the potential to significantly accelerate the drug discovery process and to bring new drugs to market faster.
• Strong pipeline of drug candidates: Exscientia has a pipeline of over 20 drug candidates in development, targeting a wide range of therapeutic areas.
• Partnerships with leading pharmaceutical companies: Exscientia's partnerships with leading pharmaceutical companies give it access to the funding, expertise, and resources it needs to develop and commercialize its drug candidates.

However, it is important to note that Exscientia is still a relatively new company and faces a number of challenges, such as competition from other AI drug discovery companies, regulatory hurdles, and the lack of profitability.

Wrapping Things Up

So that's the end of post covering Keith Kohl's new stock teaser.

The company he's pitching is Exscientia and there's a lot to like about this comapny. 

Exscientia is a pioneer in the use of AI for drug discovery. The company's work has the potential to revolutionize the way that new drugs are developed, and to bring new and innovative treatments to patients faster and more efficiently.

Exscientia's AI platform is able to generate and screen millions of potential drug candidates, and then select the most promising ones for further development. This process is much faster and more efficient than traditional drug discovery methods, which can take many years and cost billions of dollars.

Exscientia has a pipeline of over 20 drug candidates in development, targeting a wide range of diseases, including cancer, infectious diseases, and rare diseases. The company's first AI-designed drug candidate, EXS-20, entered clinical trials in 2020 for the treatment of solid tumors.

Exscientia is a company with a lot of potential. Its AI platform is promising, and its pipeline of drug candidates is diverse. However, it is important to note that Exscientia is still a relatively new company, and its drug pipeline is still in the early stages of development. This means that there is a lot of risk associated with investing in the company's stock.

Overall, Exscientia is a company to watch. The company has the potential to revolutionize drug discovery and bring new and innovative treatments to patients. However, investors should carefully consider their risk tolerance and investment goals before deciding whether or not to invest in Exscientia's stock.

So what do you think?

Is this company worth investing in?

Let me know in the comments below!